Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

Last updated: March 14, 2025
Sponsor: House Ear Institute
Overall Status: Active - Not Recruiting

Phase

4

Condition

Acute Rhinitis

Allergy (Pediatric)

Dizzy/fainting Spells

Treatment

Montelukast

Placebo

Clinical Study ID

NCT04815187
20203338
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults 18 years of age or older

  • Must meet all AAO-HNS 2020 criteria for definite or probable Meniere's Disease

  • Must have a skin test positive for allergy

  • Is already a candidate for treatment with montelukast for allergic rhinitis/failedfirst line over-the-counter allergy treatments

Exclusion

Exclusion Criteria:

  • Had a previous surgical procedure for treatment of vertigo

  • Currently receiving any allergy immunotherapy or taking montelukast or abeta-blocker

  • Pregnant or recent pregnancy ((≤ 8 weeks postpartum), or lactation)

  • Current hospitalization for any reason

  • Any active, acute, or chronic pulmonary disorder other than asthma

  • History of intubation for asthma

Study Design

Total Participants: 39
Treatment Group(s): 2
Primary Treatment: Montelukast
Phase: 4
Study Start date:
June 07, 2021
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • House Ear Clinic

    Los Angeles, California 90057
    United States

    Site Not Available

  • House Institute Foundation

    Los Angeles, California 90057
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.